Technological Advances in Stent Therapies: a Year in Review

Coronary Artery Disease (D Feldman and V Voudris, Section Editors)
  • 59 Downloads
Part of the following topical collections:
  1. Topical Collection on Coronary Artery Disease

Abstract

Stent technology has rapidly evolved since the first stainless steel bare metal stents with substantial developments in scaffolding, polymer, drug choice, drug delivery, and elution mechanisms. Most recently, there has been the evolution of bioabsorbable vascular scaffolds, potentially eliminating the need for long-term foreign object retention. These rapid developments have led to an ever-expanding selection of new stents, making the choice of which to use in which patient challenging. Operators must balance potential short- and long-term clinical ramifications, namely stent thrombosis, in-stent restenosis, target lesion revascularization, and target lesion failure. In this review, we hope to provide insight for interventional cardiologists on the details of stent technology and how this impacts outcomes, stent selection, and duration of dual-antiplatelet therapy duration post drug-eluting stent implantation.

Keywords

Coronary artery disease Dual-antiplatelet therapy Target lesion failure Target lesion revascularization Stent therapy 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301(2):61–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375(9710):201–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Smits PC, Vlachojannis GJ, McFadden E, Royaards KJ, Wassing J, Joesoef KS, et al. Final 5-year follow-up of a randomized controlled trial of Everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice: the COMPARE trial (a trial of Everolimus-eluting stents and paclitaxel stents for coronary revascularization in daily practice). JACC Cardiovasc Interv. 2015;8(9):1157–65.CrossRefPubMedGoogle Scholar
  4. 4.
    Smits PC, et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial). J Am Coll Cardiol. 2011;58(1):11–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Palmerini T, Biondi-Zoccai G, Riva DD, Stettler C, Sangiorgi D, D'Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379(9824):1393–402.CrossRefPubMedGoogle Scholar
  6. 6.
    Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a prospective, randomized, multicenter trial to assess an Everolimus-eluting coronary stent system [PROMUS element] for the treatment of up to two de novo coronary artery lesions) trial. J Am Coll Cardiol. 2011;57(16):1700–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Kereiakes DJ, Meredith IT, Windecker S, Lee Jobe R, Mehta SR, Sarembock IJ, et al. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II randomized trial. Circ Cardiovasc Interv. 2015;8(4):e002372.CrossRefPubMedGoogle Scholar
  8. 8.
    Meredith IT, et al. Final five-year clinical outcomes in the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention. 2017. Advance online publication. Retrieved from http://www.pcronline.com/eurointervention/ahead_of_print/JAA_EIJ_EIJ-D-17-00529. Accessed 11 Nov 2017.
  9. 9.
    Meredith IT, Verheye S, Dubois CL, Dens J, Fajadet J, Carrié D, et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol. 2012;59(15):1362–70.CrossRefPubMedGoogle Scholar
  10. 10.
    von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet. 2016;388(10060):2607–17.CrossRefGoogle Scholar
  11. 11.
    Kereiakes DJ, et al. Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy. EuroIntervention. 2017;12(16):1987–94.CrossRefPubMedGoogle Scholar
  12. 12.
    Sarno G, Lagerqvist B, Olivecrona G, Varenhorst C, Danielewicz M, Hambraeus K, et al. Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Catheter Cardiovasc Interv. 2017;90(6):881–7.CrossRefPubMedGoogle Scholar
  13. 13.
    von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GAJ, Hautvast RWM, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383(9915):413–23.CrossRefGoogle Scholar
  14. 14.
    • van der Heijden LC, et al. Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial. EuroIntervention. 2017;12(17):2128–31. This reference is 3-year follow-up data from the DUTCH PEERS trial showing in 1,807 patients (99.8%, four withdrawals) no difference in all-comers randomly assigned 1:1 to treatment with ZES versus EES. The primary endpoint was target vessel failure (TVF) and was a composite of cardiac death, target vessel-related myocardial infarction or target vessel revascularization. There were no differences between the ZES and EES groups with respect to TVF (10.7% vs. 10.3%; pLog-rank=0.77) or any of the subgroups: cardiac death (3.2% vs. 3.1%; pLog-rank=0.87), target vessel-related myocardial infarction (2.8% vs. 2.2%; pLog-rank=0.44) and target vessel revascularisation (6.0% vs. 6.2%; pLog-rank=0.87). In addition, the incidence of definite or probable stent thrombosis was also similar between the two groups for patients treated with ZES (1.4%) versus EES (1.1%; pLog-rank=0.66).CrossRefPubMedGoogle Scholar
  15. 15.
    • Mauri L, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–66. Landmark trial of >9000 patients showing that extending DAPT beyond 12 months after DES implantation compared to aspirin alone significantly reduced the risks of stent thrombosis,major adverse cardiovascular and cerebrovascular events at the cost of an increased risk of bleeding.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Mauri L, Smith SC Jr. Focused update on duration of dual antiplatelet therapy for patients with coronary artery disease. JAMA Cardiol. 2016;1(6):733–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Mauri L, Yeh RW, Kereiakes DJ. Duration of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2015;372(14):1373–4.PubMedGoogle Scholar
  18. 18.
    Piccolo R, Gargiulo G, Franzone A, Santucci A, Ariotti S, Baldo A, et al. Use of the dual-antiplatelet therapy score to guide treatment duration after percutaneous coronary intervention. Ann Intern Med. 2017;167(1):17–25.CrossRefPubMedGoogle Scholar
  19. 19.
    D'Ascenzo F, Moretti C, Bianco M, Bernardi A, Taha S, Cerrato E, et al. Meta-analysis of the duration of dual antiplatelet therapy in patients treated with second-generation drug-eluting stents. Am J Cardiol. 2016;117(11):1714–23.CrossRefPubMedGoogle Scholar
  20. 20.
    Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ. 2013;347:f6625.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Jad Raffoul
    • 1
  • Ammar Nasir
    • 1
    • 2
  • Andrew J. P. Klein
    • 1
    • 3
  1. 1.St. Louis University School of MedicineSaint LouisUSA
  2. 2.John Cochran Division - Veterans Administration Saint Louis Health Care SystemSaint LouisUSA
  3. 3.Interventional Cardiology, Vascular and Endovascular MedicinePiedmont Heart InstituteAtlantaUSA

Personalised recommendations